Personalized immunomonitoring using flow cytometry can aid in early detection and intervention for DN patients by monitoring CD33dim HLA DR + CD11b + AC, CD16-CD56 on HLA DR + NK cell and CD45 on HLA DR + T cell. This evidence concerns the gene NCAM1 and liver dysplastic nodule.